Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Evaluation of Nucleotide-Binding Oligomerization Domain-Containing Protein (NOD) 1 and NOD 2

NCT07160894 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-09-15
Last updated
2025-09-08

Condition(s) studied

Periodontal Diseases Inflammation

Investigational drug(s) / intervention(s)

Saliva and Serum samplingSaliva and Serum sampling

Saliva and Serum sampling: Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 5 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.

Saliva and Serum sampling: ELISA method will be used to measure IL-10 and IL-6 values in collected saliva and serum samples. For ELISA analysis, a commercial kit (Sunred Bio, Shanghai, China) pre-coated with human selected antibodies will be used.

Study summary

The host immune response to microorganisms is primarily recognized by pattern recognition receptors (PRRs), including toll-like receptors and nucleotide-binding oligomeric domain (NOD) receptors (NLRs). The aim of this study was to examine the relationship between periodontal disease and NOD in serum and saliva samples.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * systemically healthy * clinical diagnosis of periodontal health * clinical diagnosis of periodontitis * clinical diagnosis of gingivitis Exclusion Criteria: * • history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months) * nonsurgical periodontal treatment (previous 6 months) * surgical periodontal treatment (previous 12 months) * presence of\<10 teeth * current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy) * diabetes * diagnosis of rheumatoid arthritis * pregnancy * lactating * smoking * excessive alcohol consumption.

Primary outcome measure(s)

  • Pocket probing depth — 6 months
    Measurement of the depth of a sulcus or periodontal pocket determined by measuring distance from a gingival margin to the base of the sulcus or pocket with a calibrated periodontal probe.
  • Clinical attachment level — 6 months
    Clinical attachment level (or loss, CAL) is a more accurate indicator of the periodontal support around a tooth than probing depth alone. CAL is measured from a fixed point on the tooth that does not change, the CEJ. To calculate CAL, two measurements are needed: distance from the gingival margin to the CEJ and probing depth. In recession: probing depth (+) gingival margin to the CEJ (add). In tissue overgrowth: probing depth (-) gingival margin to the CEJ (subtract)
  • Bleeding on probing — 6 months
    Referring to bleeding that is induced by gentle manipulation of the tissue at the depth of the gingival sulcus, or interface between the gingiva and a tooth.

Trial sites (1)

FacilityCityRegionStatus
Istanbul Medipol University, School of Dentistry Istanbul Fatih
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07160894 on ClinicalTrials.gov ↗ ← All trials in Turkey